Streetbeat News

Products Services

ATOS

LLY

Atossa Therapeutics announced protocol changes in its clinical trial evaluating (Z)-endoxifen in combination with Eli Lilly's abemaciclib for treating ER+/HER2- breast cancer.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:36 pm

MIRM

Mirum Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for chenodiol, aimed at treating cerebrotendinous xanthomatosis (CTX). This submission is based on positive results from the Phase 3 RESTORE study. If approved, chenodiol would be the first and only therapy indicated for CTX in the US. Mirum holds orphan designation for this drug.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:36 pm

INBS

Intelligent Bio Solutions (INBS) has completed the in-clinic portion of its pharmacokinetic study, marking a significant milestone in its research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:34 pm

PLUG

Plug Power Inc (NASDAQ:PLUG) plans to leverage the Inflation Reduction Act’s Section 45V Credit for the Production of Clean Hydrogen in its upcoming quarterly financial reports. This development positions Plug Power among the first U.S. clean hydrogen producers to utilize this new incentive, which has sent the stock price higher. The PTC offers up to $3.00 per kilogram for clean hydrogen produced in the U.S., making hydrogen production more cost-competitive with traditional fossil fuels. This benefit will significantly lower Plug Power’s fuel costs and help achieve a break-even fuel margin by year-end, with positive fuel margins expected in 2025 and beyond. Plug Power’s 15-ton-per-day electrolytic hydrogen plant in Georgia, the largest in the U.S., marks a significant milestone in the company’s efforts to build a vertically integrated hydrogen ecosystem. Additionally, Plug operates a 10 TPD plant in Tennessee and plans to open a 15 TPD liquid hydrogen facility in Louisiana by the end of 2024. The company is also working on future plant developments across the U.S. and collaborating with key strategic suppliers to expand its green hydrogen network. Despite a 74% stock loss in the last 12 months and a first-quarter fiscal 2024 net revenue decline of 42.8% year-over-year, PLUG shares are trading higher by 3.25% to $2.54 premarket on Friday.

Portfolio Pulse from Anusuya Lahiri

June 28, 2024 | 12:33 pm

APIE

DFIV

HSBC

Thousands of HSBC Holdings plc customers in Britain faced an online banking outage, affecting access to their accounts and bill payments. The outage was reported by over 7,000 customers. HSBC recently acquired Citigroup Inc.'s retail wealth management portfolio in China. HSBC shares have gained 12% in the last 12 months.

Portfolio Pulse from Lekha Gupta

June 28, 2024 | 12:24 pm

BTCUSD

ETHUSD

SOLUSD

A new report by GSR suggests that the approval of a Solana (SOL) ETF could lead to significant price increases for SOL, with potential scenarios ranging from a 1.4x to an 8.9x price surge. The report highlights the changing regulatory environment under a Trump administration as a key factor.

Portfolio Pulse from Murtuza Merchant

June 28, 2024 | 12:23 pm

AIXI

Xiao-I Corporation (NASDAQ:AIXI) has announced a partnership with a leading telecommunications provider to deploy its AI Chatbot solution in Q2. This collaboration aims to enhance customer service efficiency, reduce operational costs, and provide 24/7 personalized support.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:22 pm

ARDX

Ardelyx presented new data on the educational needs for managing IBS-C at the 2024 AANP Annual Conference, highlighting the importance of cross-discipline healthcare education.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:19 pm

NVDA

SMH

SOXX

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) received government approval to invest an additional $10.26 billion in its second fabs in Kumamoto, Japan, and Arizona, USA. This investment aims to enhance advanced process technologies and meet the growing demand for AI and other applications. TSMC stock is trading higher on this news.

Portfolio Pulse from Anusuya Lahiri

June 28, 2024 | 12:13 pm

NRXP

NRx Pharmaceuticals plans to file two New Drug Applications (NDAs) in 2024 for NRX-101 and NRX-100, targeting bipolar depression, akathisia, and suicidal depression. These drugs have received Breakthrough Therapy and Fast Track Designations, respectively. Potential revenue from these drugs could exceed $150 per NRXP share. Additionally, HOPE Therapeutics is progressing towards a public listing.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:11 pm